SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
CardiovascularResearch-onlyVendors pending
Research-onlyVendors pendingFacts verified · 2026-05-25

Cardiogen

Also known as aedr, cardiocytogen

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg, AEDR) from the Khavinson short-peptide bioregulator family, designed as a fragment mimetic of cardiac-tissue extracts. It is marketed in Russia for cardiac support and is positioned in the longevity research community as a tissue-specific bioregulator for cardiomyocyte metabolism. There are no published human clinical trials in peer-reviewed Western literature, no Western regulatory approval, and essentially no independent replication of efficacy claims. All published work originates from the Khavinson group in St. Petersburg, and the compound should be considered investigational.

—

best

price

—

per

mg

—

vendors

tracked

Research-only

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Cardiogen is a synthetic AEDR tetrapeptide framed as a Khavinson cardiac bioregulator. The proposed mechanism (Khavinson, PMID 19827673) is selective tissue-specific upregulation of cardiomyocyte gene expression via direct interaction with gene promoter regions, supporting myocardial cell metabolism, protein synthesis, and resistance to ischemic stress.

Cardiogen is a synthetic AEDR tetrapeptide framed as a Khavinson cardiac bioregulator. The proposed mechanism (Khavinson, PMID 19827673) is selective tissue-specific upregulation of cardiomyocyte gene expression via direct interaction with gene promoter regions, supporting myocardial cell metabolism, protein synthesis, and resistance to ischemic stress. No defined membrane receptor is identified, and the 'direct DNA binding by short peptides' framework remains controversial and largely unconfirmed in independent Western biochemistry. Effects are characterized as epigenetic/transcriptional rather than receptor-mediated (Khavinson, PMID 27909961), and the model has not been validated by mainstream structural-biology groups.

Pharmacokinetic properties

Half-life

Unknown — no published human PK data; presumed minutes for free tetrapeptide in plasma

Routes

subcutaneous · intramuscular · intranasal

Bioavailability

Oral bioavailability not established. Russian studies have used parenteral and intranasal routes. Self-experimentation typically uses subcutaneous injection.

Amino-acid sequence

Ala-Glu-Asp-Arg (AEDR)

Use & research dosing

Cardiac SupportTissue RepairRecovery

Russian protocols and self-experimentation reports use 100-300 mcg subcutaneous daily for 10-20 day cycles, repeated 1-2 times per year. No clinically established Western human dose exists and no Western pharmacokinetic data are available. Russian oral capsule products are typically labeled around 200 mcg total peptide content per capsule, dosed once or twice daily. Research framing only — no clinical dose recommendation.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Current state: Cardiogen exists almost entirely within the Khavinson bioregulator research ecosystem. Without independent replication or Western controlled trials, claims about cardiomyocyte gene-expression modulation should be treated as preliminary. The product is sold globally as a research peptide but should not be framed as a clinically validated cardiac therapy.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Almost all efficacy data come from Khavinson's group; independent replication essentially absent
  • No published human PK or controlled safety data — limited safety data flag
  • Active cardiac arrhythmia or unstable ischemic disease — not a substitute for evidence-based therapy
  • Pregnancy and breastfeeding — no data
  • Vendor purity, peptide integrity, and endotoxin levels variable
  • Mechanistic claim of direct DNA binding is unverified in independent biochemistry
  • Not FDA-approved; not recognized in major Western pharmacopoeias

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/19827673/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/27909961/

Facts verified

2026-05-25

Confidence

low

What this means

  • evidence base is primarily Russian-language / Khavinson institute
  • limited safety data
  • no Western controlled trials
  • mechanistic claims (direct DNA binding) unverified independently

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.